Sign up to save your podcasts
Or
Share Naltrexone versus buprenorphine for opioid use disorder
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Naltrexone versus buprenorphine for opioid use disorder
This episode features Dr. Andrew Saxon discussing treatments for opioid use disorder. Dr. Jennifer Mitty hosts.
Dr. Saxon is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle, and he is Chair of the American Psychiatric Association's Council on Addiction Psychiatry.
References:
Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309.
Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74:1197.
Contributor Disclosure: Grant/Research/Clinical Trial Support: Medicasafe [Medication dispensing]. Consultant/Advisory Boards: Neurocrine Biosciences [Tardive dyskinesia (Valbenazine)].
View all episodes
By UpToDate
4.3
121121 ratings
This episode features Dr. Andrew Saxon discussing treatments for opioid use disorder. Dr. Jennifer Mitty hosts.
Dr. Saxon is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle, and he is Chair of the American Psychiatric Association's Council on Addiction Psychiatry.
References:
Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309.
Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74:1197.
Contributor Disclosure: Grant/Research/Clinical Trial Support: Medicasafe [Medication dispensing]. Consultant/Advisory Boards: Neurocrine Biosciences [Tardive dyskinesia (Valbenazine)].